Clinical Trials Logo

Acute Myeloid Leukemia clinical trials

View clinical trials related to Acute Myeloid Leukemia.

Filter by:

NCT ID: NCT05979675 Recruiting - Clinical trials for Acute Myeloid Leukemia

Acute Myeloid Leukemia Registry

AMLREGISTRY
Start date: December 21, 2021
Phase:
Study type: Observational [Patient Registry]

All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this study.

NCT ID: NCT05961839 Recruiting - Clinical trials for Acute Myeloid Leukemia

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Start date: September 27, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.

NCT ID: NCT05955261 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Start date: July 25, 2023
Phase: Phase 2
Study type: Interventional

This is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients with newly diagnosed acute myeloid leukemia (AML). Primary Objectives: - Establish the tolerability adding venetoclax to standard chemotherapy in pediatric patients with AML - Estimate the proportion of patients who become minimal residual disease (MRD) negative by flow cytometry after one course of venetoclax-based induction therapy Secondary Objectives: - Estimate the rates of complete remission (CR), event-free survival (EFS), and overall survival (OS) in pediatric patients who receive venetoclax-based chemotherapy

NCT ID: NCT05949762 Recruiting - Clinical trials for Acute Myeloid Leukemia

Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly

Start date: April 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective phase II, single-arm clinical study that plans to enroll 45 patients aged 60 years or older with primary AML diagnosed after April 1, 2023.The purpose of this trial is to evaluate the efficacy of Venetoclax in combination with azacitidine and HA regimens in elderly patients aged >60 years with primary acute myeloid leukemia and to provide evidence for optimal selection of clinical treatment regimens.

NCT ID: NCT05941585 Recruiting - Clinical trials for Acute Myeloid Leukemia

Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia

Start date: August 8, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the safety, efficacy and pharmacokinetics of mitoxantrone hydrochloride liposome injection combined with chemotherapy in previously untreated de novo acute myeloid leukemia.

NCT ID: NCT05939180 Recruiting - Clinical trials for Acute Myeloid Leukemia

VA vs DA for Newly Diagnosed Hig-risk AML

Start date: April 1, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This is an open-label, multicenter, phase 2b, randomized study aiming to compare the efficacy and safety of venetoclax plus azacytidine Versus daunorubicin plus cytarabine (conventional 7+3 regimen) in adult acute myeloid leukemia (AML) patients with adverse risk featuress. Participants will be 1:1 randomly assigned to the VA and DA groups. Once remission was achieved, consolidated chemotherapy will be performed and allogeneic hematopoietic stem cell transplantation is strongly recommended. After completion of the study intervention, participants will be followed-up every 1 to 2 months for up to 2 years.

NCT ID: NCT05918692 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Phase 1, Study of BMF-500 in Adults With Acute Leukemia

Start date: July 26, 2023
Phase: Phase 1
Study type: Interventional

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.

NCT ID: NCT05918198 Recruiting - Clinical trials for Acute Myeloid Leukemia

Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to test the safety and efficacy of venetoclax plus CAG regimen in refractory/relapsed acute myeloid leukemia patients.

NCT ID: NCT05909293 Recruiting - Clinical trials for Acute Myeloid Leukemia

Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission

Start date: April 12, 2023
Phase: N/A
Study type: Interventional

This clinical study evaluates the efficacy and safety of maintenance therapy with BCL-2 inhibitors in elderly patients with acute myeloid leukemia (AML) in first complete remission. This study involves the following content: BCL-2 inhibitors.

NCT ID: NCT05893472 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML.

Start date: April 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of the combination of venetoclax and HAA regimen in young, newly diagnosed acute myeloid leukemia patients under the age of 60.